Management of Inherited and sporadic medullary thyroid cancer (MTC) is a challenge for clinicians. Inherited MTC syndromes (multiple endocrine neoplasia type 2, MEN 2) affect approximately 1 in 30,000 individuals and consist of MEN 2A (Sipple’s syndrome), familial MTC (FMTC), and MEN 2B. This article discusses the American Thyroid Society’s recommendations for diagnosis and treatment of MTC. Medullary thyroid cancer is the third most common type of thyroid cancer with overall 10-year survival rates of 90%.
However, the survival rate is only 20% when the cancer spread to distant sites. The American thyroid society have given following recommendations as initial diagnosis and management of MTC. This guideline describes the initial diagnosis and therapy of preclinical disease in MEN 2 syndromes and clinically apparent disease. Further, it also discusses initial evaluation and treatment of…
